Drugs Made In Stock Today
| DMAA Stock | 10.45 0.02 0.19% |
PerformanceGood
| Odds Of DistressLow
|
Drugs Made is trading at 10.45 as of the 20th of February 2026, a 0.19 percent up since the beginning of the trading day. The stock's open price was 10.43. Drugs Made has only a 7 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 22nd of November 2025 and ending today, the 20th of February 2026. Click here to learn more.
Business Domain Financial Services | IPO Date 25th of February 2025 | Classification Financials |
Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 33.52 M outstanding shares of which 36.31 K shares are currently shorted by private and institutional investors with about 3.32 trading days to cover. More on Drugs Made In
Moving together with Drugs Stock
Moving against Drugs Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Drugs Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Chairman | Lynn Stockwell |
| Business Concentration | Diversified Capital Markets, Financial Services, NASDAQ Composite, Financials, Capital Markets, Shell Companies, Industrials (View all Sectors) |
| Financial Strength | |
Drugs Made In (DMAA) is traded on NASDAQ Exchange in USA and employs 3 people. Drugs Made is listed under Diversified Capital Markets category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 349.58 M. Drugs Made In conducts business under Capital Markets sector and is part of Financials industry. The entity has 33.52 M outstanding shares of which 36.31 K shares are currently shorted by private and institutional investors with about 3.32 trading days to cover.
Check Drugs Made Probability Of Bankruptcy
Ownership AllocationDrugs Made holds a total of 33.52 Million outstanding shares. The majority of Drugs Made In outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Drugs Made In to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Drugs Made. Please pay attention to any change in the institutional holdings of Drugs Made In as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Drugs Ownership Details
Drugs Made In Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Drugs Made market risk premium is the additional return an investor will receive from holding Drugs Made long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0512 | |||
| Jensen Alpha | 0.0075 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | (0.26) |
Drugs Stock Against Markets
Drugs Made Corporate Executives
Elected by the shareholders, the Drugs Made's board of directors comprises two types of representatives: Drugs Made inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Drugs. The board's role is to monitor Drugs Made's management team and ensure that shareholders' interests are well served. Drugs Made's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Drugs Made's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saleem CPA | CFO Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Drugs Made In. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Diversified Capital Markets space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Drugs Made assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Drugs Made In is measured differently than its book value, which is the value of Drugs that is recorded on the company's balance sheet. Investors also form their own opinion of Drugs Made's value that differs from its market value or its book value, called intrinsic value, which is Drugs Made's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Drugs Made's market value can be influenced by many factors that don't directly affect Drugs Made's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Drugs Made's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.